|
1
|
Luo J, Solimini NL and Elledge SJ:
Principles of cancer therapy: Oncogene and non-oncogene addiction.
Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar
|
|
3
|
Yu X, Yang L, Cairns MJ, Dass C, Saravolac
E, Li X and Sun LQ: Chemosensitization of solid tumors by
inhibition of Bcl-xL expression using DNAzyme. Oncotarget.
5:9039–9048. 2014.PubMed/NCBI
|
|
4
|
Gazzaniga P, Gradilone A, Silvestri I,
Gandini O, Giuliani L, Vincenzoni A, Gallucci M, Frati L and
Agliano AM: Variable levels of bcl-2, bcl-x and bax mRNA in bladder
cancer progression. Oncol Rep. 5:901–904. 1998.PubMed/NCBI
|
|
5
|
Giménez-Bonafé P, Tortosa A and
Pérez-Tomás R: Overcoming drug resistance by enhancing apoptosis of
tumor cells. Curr Cancer Drug Targets. 9:320–340. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Youssef RF and Lotan Y: Predictors of
outcome of non-muscle-invasive and muscle-invasive bladder cancer.
Sci World J. 11:369–381. 2011. View Article : Google Scholar
|
|
7
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A:
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duggan BJ, Gray S, Johnston SR, Williamson
K, Miyaki H and Gleave M: The role of antisense oligonucleotides in
the treatment of bladder cancer. Urol Res. 30:137–147. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshimine S, Kikuchi E, Kosaka T, Mikami
S, Miyajima A, Okada Y and Oya M: Prognostic significance of Bcl-xL
expression and efficacy of Bcl-xL targeting therapy in urothelial
carcinoma. Br J Cancer. 108:2312–2320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lebedeva I, Raffo A, Rando R, Ojwang J,
Cossum P and Stein CA: Chemosensitization of bladder carcinoma
cells by bcl-xL antisense oligonucleotides. J Urol. 166:461–469.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Achenbach TV, Brunner B and Heermeier K:
Oligonucleotide-based knockdown technologies: Antisense versus RNA
interference. Chem Biochem. 4:928–935. 2003.
|
|
13
|
Scherer LJ and Rossi JJ: Approaches for
the sequence-specific knockdown of mRNA. Nat Biotechnol.
21:1457–1465. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bolenz C, Becker A, Trojan L, Schaaf A,
Cao Y, Weiss C, Alken P and Michel MS: Optimizing chemotherapy for
transitional cell carcinoma by application of bcl-2 and bcl-xL
antisense oligodeoxynucleotides. Urol Oncol. 25:476–482. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Littlejohn JE, Cao X, Miller SD, Ozvaran
MK, Jupiter D, Zhang L, Rodarte C and Smythe WR: Bcl-xL antisense
oligo-nucleotide and cisplatin combination therapy extends survival
in SCID mice with established mesothelioma xenografts. Int J
Cancer. 123:202–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kunze D, Erdmann K, Froehner M, Wirth MP
and Fuessel S: siRNA-mediated inhibition of antiapoptotic genes
enhances chemotherapy efficacy in bladder cancer cells. Anticancer
Res. 32:4313–4318. 2012.PubMed/NCBI
|
|
17
|
Bolenz C, Weiss C, Wenzel M, Gabriel U,
Steidler A, Becker A, Herrmann E, Trojan L and Michel MS: In vivo
evaluation of intravesical paclitaxel and combined bcl-xL antisense
oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
J Cancer Res Clin Oncol. 135:679–686. 2009. View Article : Google Scholar
|
|
18
|
Gabriel U, Bolenz C, Becker A, Schaaf A,
Steidler A, Trojan L, Weiss C and Michel MS: Evaluation of
cytotoxic effects induced by bcl-2 and bcl-xL
antisense-oligodeoxynucleotides in normal urothelium and
transitional cell carcinoma. Oncol Rep. 20:1419–1423.
2008.PubMed/NCBI
|
|
19
|
Kraemer K, Fuessel S, Schmidt U, Kotzsch
M, Schwenzer B, Wirth MP and Meye A: Antisense-mediated hTERT
inhibition specifically reduces the growth of human bladder cancer
cells. Clin Cancer Res. 9:3794–3800. 2003.PubMed/NCBI
|
|
20
|
Kirsh EJ, Baunoch DA and Stadler WM:
Expression of bcl-2 and bcl-X in bladder cancer. J Urol.
159:1348–1353. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kunze D, Wuttig D, Fuessel S, Kraemer K,
Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget
siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in
bladder cancer cells. Anticancer Res. 28B:2259–2263. 2008.
|
|
22
|
Chan JH, Lim S and Wong WS: Antisense
oligonucleotides: From design to therapeutic application. Clin Exp
Pharmacol Physiol. 33:533–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lebedeva I, Rando R, Ojwang J, Cossum P
and Stein CA: Bcl-xL in prostate cancer cells: Effects of
overexpression and down-regulation on chemosensitivity. Cancer Res.
60:6052–6060. 2000.PubMed/NCBI
|
|
24
|
Fuessel S, Herrmann J, Ning S, Kotzsch M,
Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A:
Chemosensitization of bladder cancer cells by survivin-directed
antisense oligodeoxy-nucleotides and siRNA. Cancer Lett.
232:243–254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miyagishi M, Hayashi M and Taira K:
Comparison of the suppressive effects of antisense oligonucleotides
and siRNAs directed against the same targets in mammalian cells.
Antisense Nucleic Acid Drug Dev. 13:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bertrand JR, Pottier M, Vekris A, Opolon
P, Maksimenko A and Malvy C: Comparison of antisense
oligonucleotides and siRNAs in cell culture and in vivo. Biochem
Biophys Res Commun. 296:1000–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kretschmer-Kazemi Far R and Sczakiel G:
The activity of siRNA in mammalian cells is related to structural
target accessibility: A comparison with antisense oligonucleotides.
Nucleic Acids Res. 31:4417–4424. 2003. View Article : Google Scholar : PubMed/NCBI
|
